Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma Read more
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio Read more
AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer Read more
Orchard Therapeutics Receives FDA Approval of Lenmeldy (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S. Read more
Next Gen Peptide Formulation & Delivery Summit: Unleash Peptide Potential Through Cutting-Edge Delivery Innovations Read more
FDA Oncologic Drugs Advisory Committee recommends CARVYKTI (ciltacabtagene autoleucel) for the earlier treatment of patients with relapsed or refractory multiple myeloma Read more
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases Read more